Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Pure Storage (P) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Pure StorageTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Pure Storage vs State Street SPDR S&P Biotech ETF — how do they compare? Pure Storage trades at $98.27 (market cap $33.70B), while State Street SPDR S&P Biotech ETF trades at $159.93. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Pure Storage nearer its low. Which is the better fit depends on your goals.

PXBI
Market Cap
$33.70B
Sector
TechnologyBroad Market / Factor
52-Week High
$118.16$169.55
52-Week Low
$56.99$93.43
Enterprise Value
$32.92B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Pure Storage

No Aura AI signal available yet.

State Street SPDR S&P Biotech ETF

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Pure Storage

Pure Storage develops enterprise data storage and data management systems, primarily using all-flash technology. Its platform supports cloud, AI, analytics, and mission-critical application workloads.

Read more on P

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI